
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : LianBio
Deal Size : Inapplicable
Deal Type : Inapplicable
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
Details : MYK-461 (mavacamten) is the first and only cardiac myosin inhibitor, that demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : LianBio
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being investigated for treatment of symptomatic obstructive HCM which is a progressive disease that thickens heart walls and makes it harder for the heart to expand normally and...
Product Name : Camzyos
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NDA submission was based on the results of the pivotal Phase 3 EXPLORER-HCM trial, which evaluated mavacamten in patients with symptomatic oHCM versus placebo.
Product Name : Camzyos
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2021
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $13,100.0 million
Deal Type : Acquisition
Details : Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease with high morbidity and patient impact...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $13,100.0 million
November 17, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $13,100.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten
Details : Mavacamten treatment resulted in favorable effect on cardiac structure -- significantly reduced hypertrophy in patients with hypertrophic cardiomyopathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : American College of Cardiology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : MyoKardia and American College of Cardiology reported establishment of a nationwide registry of hypertrophic cardiomyopathy. The registry will support MyoKardia’s post-marketing safety and effectiveness study of mavacamten.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 11, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : American College of Cardiology
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Two of the abstracts accepted for presentation focus on echocardiographic and cardiac magnetic resonance imaging (CMR) data from the pivotal EXPLORER-HCM clinical trial of mavacamten.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $13,100.0 million
Deal Type : Acquisition
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Details : The acquisition provides Bristol Myers Squibb access to Mavacamten, a potential first-in-class myosin inhibitor with compelling data in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $13,100.0 million
October 05, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $13,100.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Danicamtiv
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2020
Lead Product(s) : Danicamtiv
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : LianBio
Deal Size : $187.0 million
Deal Type : Collaboration
Details : The partnership will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow, in keeping with MyoKardia’s development strategy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 11, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : LianBio
Deal Size : $187.0 million
Deal Type : Collaboration
